Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Regeneron Pharmaceuticals Stock: Is REGN Underperforming the Healthcare Sector?

Regeneron Pharmaceuticals, Inc. (REGN) is a leading American biotechnology company headquartered in Tarrytown, New York. Valued at $52.9 billion by market cap, the company focuses on discovering, developing, manufacturing, and commercializing medicines for serious diseases.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and REGN perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. Its market leadership lies in its cutting-edge proprietary technologies like VelociSuite®, which enable rapid development of innovative antibody therapies. It boasts a strong and diverse product portfolio, including blockbuster drugs such...

Fundamentals

See More
  • Market Capitalization, $K 12,990,484
  • Shares Outstanding, K 193,570
  • Annual Sales, $ 4,241 M
  • Annual Income, $ 32,610 K
  • EBIT $ 175 M
  • EBITDA $ 264 M
  • 60-Month Beta 0.67
  • Price/Sales 2.98
  • Price/Cash Flow 117.52
  • Price/Book 3.43

Options Overview Details

View History
  • Implied Volatility 35.67% ( -2.10%)
  • Historical Volatility 24.60%
  • IV Percentile 52%
  • IV Rank 36.67%
  • IV High 63.71% on 03/11/25
  • IV Low 19.43% on 06/12/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 2,870
  • Volume Avg (30-Day) 668
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 18,911
  • Open Int (30-Day) 19,337

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 1.11
  • Number of Estimates 8
  • High Estimate 1.18
  • Low Estimate 1.05
  • Prior Year -2.03
  • Growth Rate Est. (year over year) +154.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
57.77 +16.17%
on 05/08/25
70.97 -5.44%
on 06/03/25
+4.58 (+7.32%)
since 05/02/25
3-Month
53.56 +25.30%
on 04/09/25
72.81 -7.83%
on 03/07/25
-3.15 (-4.48%)
since 03/03/25
52-Week
53.56 +25.30%
on 04/09/25
83.95 -20.06%
on 11/08/24
+8.31 (+14.13%)
since 06/03/24

Most Recent Stories

More News
Regeneron Pharmaceuticals Stock: Is REGN Underperforming the Healthcare Sector?

Regeneron Pharmaceuticals has lagged behind the broader healthcare sector over the past year, still analysts are highly optimistic about the stock’s prospects.

XLV : 133.03 (+0.23%)
INCY : 67.11 (+2.76%)
REGN : 487.86 (-0.60%)
SNY : 49.19 (unch)
Is Wall Street Bullish or Bearish on Incyte Stock?

Despite Incyte’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

BAC : 44.65 (+1.29%)
$SPX : 5,970.37 (+0.58%)
IBB : 124.83 (+0.91%)
INCY : 67.11 (+2.76%)
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte Corporation INCY reported first-quarter 2025 adjusted earnings of $1.16 per share, which beat the Zacks Consensus Estimate of $1.01. The company had recorded adjusted earnings of 58 cents per share...

BAYRY : 7.1200 (-1.66%)
LLY : 750.78 (+0.49%)
INCY : 67.11 (+2.76%)
NVS : 115.94 (-0.65%)
3 Value Stocks Facing Headwinds

3 Value Stocks Facing Headwinds

CARS : 10.36 (+1.97%)
MTCH : 30.44 (+0.41%)
INCY : 67.11 (+2.76%)
3 Value Stocks Facing Headwinds

3 Value Stocks Facing Headwinds

CARS : 10.36 (+1.97%)
MTCH : 30.44 (+0.41%)
INCY : 67.11 (+2.76%)
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

INCY : 67.11 (+2.76%)
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers

INCY : 67.11 (+2.76%)
Incyte: Q1 Earnings Snapshot

Incyte: Q1 Earnings Snapshot

INCY : 67.11 (+2.76%)
Incyte (INCY) Q1 Earnings Report Preview: What To Look For

Incyte (INCY) Q1 Earnings Report Preview: What To Look For

INCY : 67.11 (+2.76%)
ABBV : 187.25 (+0.14%)
GILD : 109.33 (+0.39%)
3 Cash-Heavy Stocks Skating on Thin Ice

3 Cash-Heavy Stocks Skating on Thin Ice

MOV : 16.23 (-0.31%)
INCY : 67.11 (+2.76%)
SONO : 10.22 (+1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 76.73
2nd Resistance Point 73.85
1st Resistance Point 70.48
Last Price 67.11
1st Support Level 64.23
2nd Support Level 61.35
3rd Support Level 57.98

See More

52-Week High 83.95
Fibonacci 61.8% 72.34
Fibonacci 50% 68.75
Last Price 67.11
Fibonacci 38.2% 65.17
52-Week Low 53.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »